Press Releases

2016

December 27, 2016 Aduro Biotech to Present at the 35th Annual J.P. Morgan Healthcare Conference


December 06, 2016 Aduro Biotech Europe’s Hans van Eenennaam, Ph.D. and John Dulos, Ph.D. Honored with the Intellectual Property Owners Education Foundation’s 43rd Inventor of the Year Award for Contributions in the Discovery of KEYTRUDA® (pembrolizumab)


December 05, 2016 Aduro Biotech Announces Anti-CD27 Agonist, an Investigational Anti-Cancer Immunotherapy, Advancing in Collaboration with MSD


December 03, 2016 Aduro Biotech Presents Preclinical Data Supporting Clinical Development of its Anti-APRIL Antibody, BION-1301, for the Treatment of Multiple Myeloma


November 21, 2016 Partial Clinical Hold Lifted and Enrollment Resumes for Aduro Biotech LADD Clinical Trials


November 12, 2016 Aduro Biotech Highlights Positive Clinical Results from Second Cohort of Phase 1b Mesothelioma Clinical Trial


November 09, 2016 Aduro Biotech’s Personalized LADD Therapy Featured in an Oral Presentation at SITC’s New Cancer Immunotherapy Agents in Development Program


November 07, 2016 Aduro Biotech Presents Preclinical Data Demonstrating Acute and Systemic Immune Activation through STING Pathway Stimulation with ADU-S100


November 02, 2016 Aduro Biotech Reports Third Quarter 2016 Financial Results


October 24, 2016 Aduro Biotech Reports Partial Clinical Hold to Pause Enrollment in LADD Trials


October 23, 2016 Aduro Biotech to Host Conference Call


September 27, 2016 Aduro Biotech Presents Encouraging Preclinical Data Showing Combination Synergy of its Immunotherapy and Checkpoint Inhibitors to Increase Antitumor Efficacy


September 26, 2016 Aduro Biotech’s Stephen T. Isaacs Named 2016 Visionary Leader by Berkeley Chamber of Commerce


September 22, 2016 Aduro Biotech to Present at LEERINK Partners Roundtable Series


September 06, 2016 Aduro Biotech Appoints Oncology Expert and Industry Veteran Natalie Sacks, M.D. as Chief Medical Officer


September 01, 2016 Aduro Biotech Announces New Corporate Offices and Laboratory Space


August 04, 2016 Aduro Biotech to Present at Canaccord Genuity Growth Conference


August 03, 2016 Aduro Biotech Reports Second Quarter 2016 Financial Results


June 09, 2016 Aduro Biotech to Present at NASDAQ Investor Conference


June 04, 2016 Aduro Biotech Presents Encouraging Anti-Tumor Response Data From Ongoing Phase 1b Study in Malignant Pleural Mesothelioma at ASCO


May 16, 2016 Aduro Biotech Announces Phase 2b ECLIPSE Trial Misses Primary Endpoint in Heavily Pretreated Metastatic Pancreatic Cancer


May 15, 2016 Aduro Biotech to Host Conference Call


May 12, 2016 Aduro Biotech Announces First Patient Dosed in Phase 1 Study of ADU-S100 for the Treatment of Cutaneously Accessible Tumors


May 11, 2016 Aduro Biotech Announces Management Promotions


May 02, 2016 Aduro Biotech Announces First Quarter 2016 Financial Results


April 28, 2016 Aduro Biotech Announces Key Preclinical Data Published Highlighting New Approach to Treat Multiple Myeloma


April 27, 2016 Aduro Biotech to Present at Two Upcoming Investor Conferences


April 11, 2016 Aduro Biotech Chief Scientific Officer to Highlight the Potential of STING Activation in Cancer Immunotherapy in a Major Symposium at the 2016 American Association for Cancer Research Annual Meeting


March 28, 2016 Aduro Biotech and UC Berkeley Launch Industry-Leading Immunotherapeutics and Vaccine Research Initiative


March 24, 2016 Aduro Biotech Announces First Patient Dosed in Combination Clinical Trial of CRS-207 and Epacadostat to Treat Ovarian Cancer


March 08, 2016 Aduro Biotech Announces Fourth Quarter and Full Year 2015 Financial Results


March 07, 2016 Aduro Biotech to Present at ROTH Conference


February 03, 2016 Aduro Biotech to Present at Leerink Partners Global Healthcare Conference


February 01, 2016 Aduro Biotech Receives $22.4 Million in Clinical Development Milestone Payments From Janssen


January 25, 2016 Aduro Biotech Appoints Aimee Luck Murphy as Vice President of Clinical Development and Operations


January 07, 2016 Aduro Biotech to Present at JP Morgan Healthcare Conference


January 05, 2016 Aduro Biotech Expands Patent Portfolio With Key Newly Issued Composition and Methods Patents